Skye Bioscience宣布，其股东将在交易完成后的12个月内，获得一项或有价值权（CVR），该权益涵盖Nimacimab项目净收益的90%。这一安排为投资者提供了明确的收益分配机制，旨在确保股东能够从该资产未来的商业化成果中直接受益。
Skye Bioscience宣布，其股东将在交易完成后的12个月内，获得一项或有价值权（CVR），该权益涵盖Nimacimab项目净收益的90%。这一安排为投资者提供了明确的收益分配机制，旨在确保股东能够从该资产未来的商业化成果中直接受益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.